Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 2/20 | 0.53 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6378087 | 0.98 | GRN (0.51) | GRNSORT1KDM4ESMYD3NAMPT | |
| SCHEMBL8508457 | 0.86 | GRN (0.55) | GRNSORT1KDM4ESMYD3NAMPT | |
| SCHEMBL28145141 | 0.86 | SMYD3 (0.42) | GRNSORT1KDM4ESMYD3NAMPT | |
| SCHEMBL28138855 | 0.86 | SMYD3 (0.42) | GRNSORT1KDM4ESMYD3NAMPT | |
| SCHEMBL727 | 0.85 | POLB (0.51) | GRNSORT1KDM4ESMYD3NAMPT | |
| SCHEMBL12646244 | 0.85 | SMYD3 (0.51) | GRNSORT1KDM4ESMYD3NAMPT | |
| SCHEMBL3410538 | 0.83 | SMYD3 (0.54) | SMYD3NAMPTKMT2AMEN1CTSV | |
| SCHEMBL22345987 | 0.83 | KDM4E (0.51) | GRNSORT1KDM4ESMYD3NAMPT | |
| SCHEMBL6378085 | 0.83 | SMYD3 (0.50) | GRNSORT1KDM4ESMYD3NAMPT | |
| SCHEMBL8507975 | 0.83 | GRN (0.51) | GRNSORT1KDM4ESMYD3NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114920734-A | 5- (pyrazole-5-yl) -1,2, 4-oxadiazole substituted benzamide compounds and preparation method and application thereof | 浙江工业大学 | 2022-08-19 | — | — | CN | claimed |
| CN-106397377-A | Electron-rich five-membered heterocyclic acid and method for decarboxylation and fluorination of derivative thereof | 中南大学 | 2017-02-15 | — | — | CN | claimed |
| CN-103556174-B | The synthetic method of a kind of 4-chloro-1-methyl-3-ethyl-5-pyrazole carboxylic acid second ester | HARBIN UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2016-06-01 | — | — | CN | claimed |
| CN-104592202-A | 3-ethyl-N-methyl-[(N-methyl-N-[(2-pyridyl)carbamoyl)phenyl]-pyrazole-5-carboxamide as well as preparation method and application thereof | WUHAN INST TECHNOLOGY | 2015-05-06 | — | — | CN | claimed |
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | claimed |
| EP-1899296-B1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2010-11-17 | — | — | EP | claimed |
| US-7812040-B2 | such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders | PFIZER INC. (US) | 2010-10-12 | — | — | US | claimed |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2009-05-21 | — | — | US | claimed |
| CN-101189228-A | Bicyclic [3.1.0] heteroaryl amides as type I glycine transport inhibitors | PFIZER PROD INC (US) | 2008-05-28 | — | — | CN | claimed |
| EP-1899296-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2008-03-19 | — | — | EP | claimed |
| EP-1869019-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | Pfizer Products Incorporated (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006136924-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-12-28 | — | — | WO | claimed |
| WO-2006106425-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-10-12 | — | — | WO | claimed |
| US-20260070924-A1 | INDAZOLE MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4536225-A1 | INDAZOLE MACROCYCLES AND THEIR USE | Blossomhill Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025049827-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING PYRAZOLE DERIVATIVES | OSMO LABS, PBC (US) | 2025-03-06 | — | — | WO | disclosed |
| US-6534524-B1 | Antiproliferative agents, including axitinib | AGOURON PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6531491-B1 | Methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, | AGOURON PHARAMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1218348-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001002369-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | HRH3, HRH4, HRH2 | GRN 3646/4885SORT1 1278/4885KDM4E 3381/4885 |
| US-20260070924-A1 | INDAZOLE MACROCYCLES AND THEIR USE | NR0B2, NR0B1, ESRRA | GRN 2033/4885SORT1 3082/4885KDM4E 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.